JP2000500019A5 - - Google Patents

Download PDF

Info

Publication number
JP2000500019A5
JP2000500019A5 JP1997518551A JP51855197A JP2000500019A5 JP 2000500019 A5 JP2000500019 A5 JP 2000500019A5 JP 1997518551 A JP1997518551 A JP 1997518551A JP 51855197 A JP51855197 A JP 51855197A JP 2000500019 A5 JP2000500019 A5 JP 2000500019A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997518551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000500019A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1996/004850 external-priority patent/WO1997018314A1/de
Publication of JP2000500019A publication Critical patent/JP2000500019A/ja
Publication of JP2000500019A5 publication Critical patent/JP2000500019A5/ja
Ceased legal-status Critical Current

Links

JP9518551A 1995-11-16 1996-11-06 ストレプトアビジン融合タンパク質経由でのペプチドの生産方法 Ceased JP2000500019A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19542702.5 1995-11-16
DE19542702 1995-11-16
PCT/EP1996/004850 WO1997018314A1 (de) 1995-11-16 1996-11-06 Verfahren zur herstellung von peptiden über streptavidin-fusionsproteine

Publications (2)

Publication Number Publication Date
JP2000500019A JP2000500019A (ja) 2000-01-11
JP2000500019A5 true JP2000500019A5 (enExample) 2004-11-04

Family

ID=7777604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9518551A Ceased JP2000500019A (ja) 1995-11-16 1996-11-06 ストレプトアビジン融合タンパク質経由でのペプチドの生産方法

Country Status (6)

Country Link
US (1) US6136564A (enExample)
EP (1) EP0861325A1 (enExample)
JP (1) JP2000500019A (enExample)
AU (1) AU7566396A (enExample)
CA (1) CA2237296C (enExample)
WO (1) WO1997018314A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168718A1 (en) * 1997-04-03 2002-11-14 California Institute Of Technology Enzyme-mediated modification of fibrin for tissue engineering
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
DK1181323T3 (da) 1999-02-01 2011-10-17 Eidgenoess Tech Hochschule Biomaterialer dannet med nukleofil additionsreaktion med konjugerede uimættede grupper
AU5597500A (en) * 1999-06-07 2000-12-28 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US7291673B2 (en) * 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
EP1465989B1 (en) * 2001-12-18 2008-02-20 Eidgenossisch Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
JP4560291B2 (ja) * 2001-12-18 2010-10-13 イジュノシッヒ テクニッヒ ホッフシューラ チューリッヒ 組織操作のための成長因子改変タンパク質マトリクス
US8282912B2 (en) * 2002-03-22 2012-10-09 Kuros Biosurgery, AG Compositions for tissue augmentation
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US20060147443A1 (en) * 2004-12-22 2006-07-06 Kuros Biosurgery Ag Synthetic biomaterials having incorporated therein bioactive factors through enzymatically degradable linkages
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
MX2007008319A (es) * 2005-01-06 2007-10-04 Kuros Biosurgery Ag Matrices suplementadas para la reparacion de fracturas oseas.
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
DK2136850T3 (da) 2007-04-13 2012-04-10 Kuros Biosurgery Ag Polymervævforsegling
WO2009083544A2 (en) * 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
EP2478013B1 (en) * 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US20120277155A1 (en) 2011-02-25 2012-11-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
EP2686027B1 (en) 2011-03-16 2021-05-05 Kuros Biosurgery AG Pharmaceutical formulation for use in spinal fusion
EP2750697A4 (en) 2011-09-02 2015-03-25 Medtronic Inc CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Fc-영역 접합체의 제조 방법 및 그의 용도
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0198015B2 (en) * 1984-10-02 1995-07-19 Biogen, Inc. Production of streptavidin-like polypeptides
GB8518753D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Microbiological products
WO1988006596A1 (en) * 1987-03-02 1988-09-07 Bissendorf Peptide Gmbh New cardiodilatin fragment, process for preparing same and use thereof
GB8723661D0 (en) * 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
ATE253639T1 (de) * 1991-08-19 2003-11-15 Daiichi Suntory Pharma Co Ltd Verfahren zur herstellung von peptiden

Similar Documents

Publication Publication Date Title
JP2000500445A5 (enExample)
JP2000500440A5 (enExample)
JP2000500327A5 (enExample)
JP2000500145A5 (enExample)
JP2000500155A5 (enExample)
JPH11507533A5 (enExample)
JP2000500406A5 (enExample)
JP2000500361A5 (enExample)
JP2000500115A5 (enExample)
JP2000500322A5 (enExample)
JP2000500258A5 (enExample)
JP2000500342A5 (enExample)
JP2000500112A5 (enExample)
JPH11506886A5 (enExample)
JP2000500407A5 (enExample)
JP2000500397A5 (enExample)
JP2000500166A5 (enExample)
JP2000500019A5 (enExample)
JP2000500125A5 (enExample)
JP2000500346A5 (enExample)
JP2000500090A5 (enExample)
JP2000500257A5 (enExample)
JPH10510459A5 (enExample)
JP2000500429A5 (enExample)
JP2000500106A5 (enExample)